You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.
The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.
The Pro-Lab Diagnostic Pro-AmpRT SARS-CoV-2 test consists of six primers and amplifies a 206 base-pair region of the ORF1ab gene of SARS-CoV-2.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
Researchers showed how an isothermal amplification technique could detect S. enterica serovars from culture by targeting specific gene markers.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
More than a dozen studies have been published to date directly comparing molecular diagnostic COVID-19 tests, with some detecting differences, mostly in sensitivity.
The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives.
The test is expected to run on Tangen's GeneSpark nucleic acid amplification platform and achieve a CLIA waiver for use in doctors' offices.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.